BIOTRONIK Announces Completion of Enrollment in the BIOLUX P-I Clinical Study Investigating Drug-eluting Balloon Therapy for Peripheral Artery Disease

BÜLACH, Switzerland - Tuesday, September 20th 2011 [ME NewsWire]

(BUSINESS WIRE)-- BIOTRONIK, a leading European manufacturer of therapy solutions for vascular intervention, announced the completion of enrollment in the BIOLUX P-I– a clinical study investigating the use of a drug-eluting balloon (DEB) catheter, a promising new approach to treating disease in the more challenging peripheral vascular anatomy.

BIOLUX P-I is a randomized controlled study investigating the safety and performance of BIOTRONIK Passeo-18 Lux, DEB catheter, versus an uncoated percutaneous transluminal angioplasty (PTA) catheter, for the treatment of lesions in the femoropopliteal segment. Sixty patients were enrolled at five centers in Germany and Austria. Primary endpoint data documenting angiographic late lumen loss (LLL) at six months is expected in the second quarter of 2012.

Drug-eluting balloons (DEBs) are emerging as an effective and durable treatment option for treating patients with de novo and restenotic arterial disease in the lower limbs. Restenosis following treatment with standard PTA balloons is a significant issue, and it is anticipated that delivery of a drug to the lesion location could significantly improve therapy efficacy.

“Drug-eluting balloons are one of the most exciting technological developments in recent years, and based on early clinical experience there is a lot of interest and promise for this new treatment option”, commented Professor Dierk Scheinert, primary investigator of BIOLUX P-I and Head of Angiology Dept, Herzzentrum/Park Hospital, Leipzig, Germany. “However, it is vital that efficacy and safety data are provided for each commercially available DEB, as outcomes may be greatly influenced by drug and coating formulations - we expect that the randomized BIOLUX P-I study will generate the positive level one clinical data that we require to confidently provide more efficacious therapy.”

The Passeo-18 Lux is coated with a homogeneous layer of the well-substantiated drug Paclitaxel combined with a carrier for increased bioavailability and optimized antiproliferative effect. The drug-carrier combination has already demonstrated early clinical efficacy in the recently presented first-in-man study “PEPPER”, investigating BIOTRONIK’s Pantera Lux DEB in coronary in-stent restenosis.

“BIOTRONIK is committed to bringing proven, high quality therapies to patients with vascular disease,” commented Alain Aimonetti, Vice President of Sales and Marketing, BIOTRONIK Vascular Intervention. “Our significant investment in clinical research continues to demonstrate BIOTRONIK’s dedication to leading the industry in finding solutions for improved patient outcomes. BIOLUX P-I is an important study in our comprehensive DEB clinical program, and aims to provide level one evidence in support of our proprietary ‘Lux’ drug coating technology”.

About BIOTRONIK SE & Co. KG

As one of the world’s leading manufacturers of cardiovascular medical devices, with several million devices implanted, BIOTRONIK is represented in over 100 countries by its global workforce of over 5,600 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success, and deliver confidence and peace of mind to physicians and their patients worldwide.

More information: www.biotronik.com

Upon publication, please provide us with a copy.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6867163&lang=en

Contacts

BIOTRONIK SE & Co. KG

Sandy Hathaway

Senior Director, Global Communications

Tel. +49 (0) 30 68905 1602

Email: sandy.hathaway@biotronik.com